The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1

Human Molecular Genetics

Volumn 23, Issue 14, 2014, Pages 3733-3745

  Venkatraman, Anand ^a   Hu, Yuan Shih ^a   Didonna, Alessandro ^a   Cvetanovic, Marija ^a,b   Krbanjevic, Aleksandar ^a   Bilesimo, Patrice ^a   Opal, Puneet ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; ATAXIN-1; HISTONE DEACETYLASE; NERVE PROTEIN; NUCLEAR PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL NUCLEUS INCLUSION BODY; CELL NUCLEUS MATRIX; CEREBELLUM DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DEFENSE MECHANISM; DEGENERATIVE DISEASE; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOINSUFFICIENCY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LUCIFERASE ASSAY; MALIGNANT NEOPLASTIC DISEASE; MORRIS WATER MAZE TEST; MOUSE; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PURKINJE CELL; SPATIAL LEARNING; SPINOCEREBELLAR ATAXIA TYPE 1; STAINING; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BODY WEIGHT; CEREBELLUM; DISEASE MODEL; GENE TARGETING; GENETICS; HEK293 CELL LINE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; SPINOCEREBELLAR ATAXIAS; TUMOR CELL LINE;

ANIMALS; BODY WEIGHT; CELL LINE, TUMOR; CEREBELLUM; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HAPLOINSUFFICIENCY; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PURKINJE CELLS; SPINOCEREBELLAR ATAXIAS;

EID: 84902957141     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu081     Document Type: Article

References (60)

1. Opal, P. and Zoghbi, H.Y. (2013) In Rimoin, D.L., Pyeritz, R.E. and Korf, B.R. (eds), In Emery and Rimoin's Principles and Practice of Medical Genetics (Sixth Edition). Academic Press, Oxford, pp. 1-32.
2. Orr, H.T. and Zoghbi, H.Y. (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci., 30, 575-621.
3. Lin, X., Antalffy, B., Kang, D., Orr, H.T. and Zoghbi, H.Y. (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat. Neurosci., 3, 157-163.
4. Serra, H.G., Byam, C.E., Lande, J.D., Tousey, S.K., Zoghbi, H.Y. and Orr, H.T. (2004) Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet., 13, 2535-2543.
5. Serra, H.G., Duvick, L., Zu, T., Carlson, K., Stevens, S., Jorgensen, N., Lysholm, A., Burright, E., Zoghbi, H.Y., Clark, H.B. et al. (2006) RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell, 127, 697-708.
6. Gatchel, J.R., Watase, K., Thaller, C., Carson, J.P., Jafar-Nejad, P., Shaw, C., Zu, T., Orr, H.T. and Zoghbi, H.Y. (2008) The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc. Natl. Acad. Sci. USA, 105, 1291-1296.
7. Cvetanovic, M., Patel, J.M., Marti, H.H., Kini, A.R. and Opal, P. (2011) Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat. Med., 17, 1445-1447.
8. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B. and Zoghbi, H.Y. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease inSCA1transgenic mice. Cell, 95, 41-53.
9. Tsai, C.C., Kao, H.Y., Mitzutani, A., Banayo, E., Rajan, H., McKeown, M. and Evans, R.M. (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA, 101, 4047-4052.
10. Cvetanovic, M., Kular, R.K. and Opal, P. (2012) LANP mediates neuritic pathology in spinocerebellar ataxia type 1. Neurobiol. Dis., 48, 526-532.
11. Tsuda, H., Jafar-Nejad, H., Patel, A.J., Sun, Y., Chen, H.K., Rose, M.F., Venken, K.J., Botas, J., Orr, H.T., Bellen, H.J. et al. (2005) TheAXHdomain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/ Senseless proteins. Cell, 122, 633-644.
12. Lam, Y.C.,Bowman,A.B., Jafar-Nejad, P., Lim, J., Richman, R., Fryer, J.D., Hyun, E.D., Duvick, L.A., Orr, H.T., Botas, J. et al. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell, 127, 1335-1347.
13. Opal, P. and Zoghbi, H.Y. (2002) The role of chaperones in polyglutamine disease. Trends Mol. Med., 8, 232-236.
14. Fernandez-Funez, P., Nino-Rosales, M.L., de Gouyon, B., She, W.C., Luchak, J.M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P.J. et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature, 408, 101-106.
15. Karagianni, P. and Wong, J. (2007) HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene, 26, 5439-5449.
16. Jia, H., Kast, R.J., Steffan, J.S. and Thomas, E.A. (2012) Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet., 21, 5280-5293.
17. Thomas, E.A., Coppola, G., Desplats, P.A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K.M., Borok, J.F., Herman, D. et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA, 105, 15564-15569.
18. New, M., Olzscha, H. and La Thangue, N.B. (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol., 6, 637-656.
19. Broide, R.S., Redwine, J.M., Aftahi, N., Young, W., Bloom, F.E. and Winrow, C.J. (2007) Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci., 31, 47-58.
20. Servadio, A., McCall, A., Zoghbi, H.Y. and Eicher, E.M. (1995) Mapping of the Sca1 and pcd genes on mouse chromosome 13 provides evidence that they are different genes. Genomics, 29, 812-813.
21. Skinner, P.J., Koshy, B., Cummings, C., Klement, I.A., Helin, K., Servadio, A., Zoghbi, H.Y. and Orr, H.T. (1997) Ataxin-1 with extra glutamines induces alterations in nuclear matrix-associated structures. Nature, 389, 971-974.
22. Zoghbi, H.Y. and Orr, H.T. (2009) Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem., 284, 7425-7429.
23. Watase, K., Weeber, E.J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D.L. et al. (2002) A long CAGrepeat in the mouseSca1 locus replicatesSCA1features and reveals the impact of protein solubility on selective neurodegeneration. Neuron, 34, 905-919.
24. Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M., Yunis, W.S., Duvick, L.A., Zoghbi, H.Y. and Orr, H.T. (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell, 82, 937-948.
25. Bhaskara, S., Chyla, B.J.,Amann,J.M., Knutson, S.K., Cortez, D., Sun,Z.W. and Hiebert, S.W. (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression andDNAdamage control. Mol. Cell, 30, 61-72.
26. Moumne, L., Campbell, K., Howland, D., Ouyang, Y. and Bates, G.P. (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS ONE, 7, e31080.
27. Watase, K., Gatchel, J.R., Sun, Y., Emamian, E., Atkinson, R., Richman, R., Mizusawa, H., Orr, H.T., Shaw, C. and Zoghbi, H.Y. (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med., 4, e182.
28. Cummings, C.J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H.T., Dillmann, W.H. and Zoghbi, H.Y. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet., 10, 1511-1518.
29. Knutson, S.K., Chyla, B.J., Amann, J.M., Bhaskara, S., Huppert, S.S. and Hiebert, S.W. (2008) Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J., 27, 1017-1028.
30. Furrer, S.A., Mohanachandran, M.S., Waldherr, S.M., Chang, C., Damian, V.A., Sopher, B.L., Garden, G.A. and LaSpada, A.R. (2011) Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. J. Neurosci., 31, 16269-16278.
31. Barski, J.J., Dethleffsen, K. and Meyer, M. (2000) Cre recombinase expression in cerebellar Purkinje cells. Genesis, 28, 93-98.
32. Komatsu, M., Wang, Q.J., Holstein, G.R., Friedrich, V.L. Jr, Iwata, J., Kominami, E., Chait, B.T., Tanaka, K. and Yue, Z. (2007) Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc. Natl. Acad. Sci. USA, 104, 14489-14494.
33. Herrup, K. and Kuemerle, B. (1997) The compartmentalization of the cerebellum. Annu. Rev. Neurosci., 20, 61-90.
34. Apps, R. and Hawkes, R. (2009) Cerebellar cortical organization: a one-map hypothesis. Nat. Rev. Neurosci., 10, 670-681.
35. Sarna, J.R. and Hawkes, R. (2003) Patterned Purkinje cell death in the cerebellum. Prog. Neurobiol., 70, 473-507.
36. Wadiche, J.I. and Jahr, C.E. (2005) Patterned expression of Purkinje cell glutamate transporters controls synaptic plasticity. Nat. Neurosci., 8, 1329-1334.
37. Kim, C.H., Oh, S.H., Lee, J.H., Chang, S.O., Kim, J. and Kim, S.J. (2012) Lobule-specific membrane excitability of cerebellar Purkinje cells. J. Physiol., 590, 273-288.
38. Sperandio, S., de Belle, I. and Bredesen, D.E. (2000) An alternative, nonapoptotic form of programmedcell death. Proc. Natl. Acad. Sci.USA, 97, 14376-14381.
39. Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P. and Davies, S.W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA, 97, 8093-8097.
40. Custer, S.K., Garden, G.A., Gill, N., Rueb, U., Libby, R.T., Schultz, C., Guyenet, S.J., Deller, T., Westrum, L.E., Sopher, B.L. et al. (2006) Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat. Neurosci., 9, 1302-1311.
41. Maltecca, F., Magnoni, R., Cerri, F., Cox, G.A., Quattrini, A. and Casari, G. (2009) Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration. J. Neurosci., 29, 9244-9254.
42. Cheung, P., Allis, C.D. and Sassone-Corsi, P. (2000) Signaling to chromatin through histone modifications. Cell, 103, 263-271.
43. Bardai, F.H., Verma, P., Smith, C., Rawat, V., Wang, L. and D'Mello, S.R. (2013) Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. J. Neurosci., 33, 11833-11838.
44. Evert, B.O., Araujo, J., Vieira-Saecker, A.M., de Vos, R.A., Harendza, S., Klockgether, T. and Wullner, U. (2006) Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci., 26, 11474-11486.
45. Duncan, C.E., An, M.C., Papanikolaou, T., Rugani, C., Vitelli, C. and Ellerby, L.M. (2013) Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Mol. Neurodegeneration, 8, 42.
46. Graff, J. and Tsai, L.H. (2013) Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci., 14, 97-111.
47. McQuown, S.C., Barrett, R.M., Matheos, D.P., Post, R.J., Rogge, G.A., Alenghat, T., Mullican, S.E., Jones, S., Rusche, J.R., Lazar, M.A. et al. (2011) HDAC3 is a critical negative regulator of long-term memory formation. J. Neurosci., 31, 764-774.
48. Kazantsev, A.G. and Thompson, L.M. (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev., 7, 854-868.
49. Sleiman, S.F., Basso, M., Mahishi, L., Kozikowski, A.P., Donohoe, M.E., Langley, B. and Ratan, R.R. (2009) Putting the 'HAT' back on survival signalling: the promises and challenges ofHDACinhibition in the treatment of neurological conditions. Exp. Opin. Invest. Drugs, 18, 573-584.
50. Bates, E.A., Victor, M., Jones, A.K., Shi, Y. and Hart, A.C. (2006) Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci., 26, 2830-2838.
51. Bardai, F.H. and D'Mello, S.R. (2011) Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J. Neurosci., 31, 1746-1751.
52. Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S. et al. (2012) Histone deacetylase (HDAC) inhibitors targetingHDAC3andHDAC1ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol. Dis., 46, 351-361.
53. Ishizuka, T. and Lazar, M.A. (2003) The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell Biol., 23, 5122-5131.
54. Montgomery, R.L., Potthoff, M.J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K.M., Richardson, J.A., Bassel-Duby, R. and Olson, E.N. (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest., 118, 3588-3597.
55. Razidlo, D.F., Whitney, T.J., Casper, M.E., McGee-Lawrence, M.E., Stensgard, B.A., Li, X., Secreto, F.J., Knutson, S.K., Hiebert, S.W. and Westendorf, J.J. (2010) Histone deacetylase 3 depletion in osteo/ chondroprogenitor cells decreases bone density and increases marrow fat. PLoS ONE, 5, e11492.
56. McGee-Lawrence, M.E., Bradley, E.W., Dudakovic, A., Carlson, S.W., Ryan, Z.C., Kumar, R., Dadsetan, M., Yaszemski, M.J., Chen, Q., An, K.N. et al. (2013) Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone, 52, 296-307.
57. Jellinek, E.H. and Kelly, R.E. (1960) Cerebellar syndrome in myxoedema. Lancet, 2, 225-227.
58. Cremer, G.M., Goldstein, N.P. and Paris, J. (1969) Myxedema and ataxia. Neurology, 19, 37-46.
59. Wagner, J.M., Hackanson, B., Lubbert, M. and Jung, M. (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet., 1, 117-136.
60. Soriano, P. (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet., 21, 70-71.